Mini Review
Volume 7:02, 2024

Journal of Clinical Neurology and Neurosurgery

ISSN: 2684-6012 Open Access

Navigating the Cognitive Terrain: Neurocognitive Changes in Patients Undergoing CAR-T Cell Therapy

Clamp Tanakabatiya*

Department of Neurology, Sapienza University of Rome, 00161 Rome, Italy

Abstract

Chimeric Antigen Receptor T-cell (CAR-T cell) therapy has emerged as a groundbreaking treatment for hematologic malignancies, offering hope to patients with relapsed or refractory disease. While CAR-T cell therapy has demonstrated remarkable efficacy in inducing tumor remission, emerging evidence suggests potential neurocognitive changes as a consequence of treatment. In this review, we explore the landscape of neurocognitive changes in patients undergoing CAR-T cell therapy, focusing on the underlying mechanisms, clinical manifestations and implications for patient care. We discuss the multifactorial nature of neurocognitive changes, including Cytokine Release Syndrome (CRS), immune-mediated neurotoxicity and Central Nervous System (CNS) infiltration of CAR-T cells. Furthermore, we examine the challenges in assessing and monitoring neurocognitive function in the context of CAR-T cell therapy and discuss strategies for mitigating cognitive sequelae and improving patient outcomes. By navigating the cognitive terrain, we aim to enhance awareness and understanding of neurocognitive changes associated with CAR-T cell therapy and optimizes supportive care measures for patients undergoing this transformative treatment approach.

Keywords: CAR-T cell therapy • Chimeric antigen receptor T-cell therapy• Neurocognitive changes • Immune-mediated neurotoxicity

Introduction

Chimeric Antigen Receptor T-cell (CAR-T cell) therapy has revolutionized the treatment landscape for hematologic malignancies, offering a promising therapeutic option for patients with relapsed or refractory disease who have exhausted standard treatment modalities. By harnessing the power of the immune system to target and eradicate cancer cells, CAR-T cell therapy has achieved unprecedented rates of complete remission and durable responses in patients with diseases such as Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-Cell Lymphoma (DLBCL) and multiple myeloma. Despite its remarkable clinical efficacy, CAR-T cell therapy is associated with a spectrum of adverse events, including Cytokine Release Syndrome (CRS), immune-mediated neurotoxicity and Central Nervous System (CNS) toxicity, which can impact various organ systems, including the brain. Emerging evidence suggests that neurocognitive changes may occur as a consequence of CAR-T cell therapy, ranging from mild cognitive dysfunction to severe encephalopathy and delirium [1].

The underlying mechanisms driving neurocognitive changes in patients undergoing CAR-T cell therapy are multifactorial and complex. CRS, characterized by systemic inflammatory responses and cytokine storm, can lead to endothelial dysfunction, blood-brain barrier disruption and neuroinflammation, contributing to cognitive impairment. Immune-mediated neurotoxicity, characterized by the activation of CAR-T cells within the CNS, can result in direct neuronal damage, neuroinflammation and alterations in neurotransmitter signaling pathways. Additionally, the infiltration of CAR-T cells into the CNS and off-target effects on normal brain tissue may further exacerbate neurocognitive dysfunction. Assessing and monitoring neurocognitive function in patients undergoing CAR-T cell therapy present significant challenges, given the heterogeneity of clinical presentations and the lack of standardized assessment tools. Furthermore, distinguishing between neurocognitive changes secondary to treatment-related toxicity and disease progression poses diagnostic dilemmas. Nevertheless, early recognition and prompt intervention are essential for mitigating cognitive sequelae and optimizing patient outcomes [2].

Literature Review

The literature on neurocognitive changes in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T cell) therapy encompasses a range of studies investigating the incidence, mechanisms, clinical manifestations and management of cognitive dysfunction associated with this revolutionary treatment approach. Several clinical trials and retrospective studies have reported neurocognitive changes in patients receiving CAR-T cell therapy for hematologic malignancies, including Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-Cell Lymphoma (DLBCL) and multiple myeloma. These changes can manifest as a spectrum of cognitive dysfunction, ranging from mild impairments in attention, memory and executive function to severe encephalopathy, delirium and coma. The incidence and severity of neurocognitive changes appear to correlate with the intensity of treatment, the presence of Cytokine Release Syndrome (CRS) and the degree of Central Nervous System (CNS) involvement [3].

The underlying mechanisms driving neurocognitive changes in patients undergoing CAR-T cell therapy are multifactorial and complex. CRS, a systemic inflammatory response triggered by CAR-T cell activation, can lead to endothelial dysfunction, blood-brain barrier disruption and neuroinflammation, resulting in cognitive impairment. Additionally, immune-mediated neurotoxicity, characterized by the infiltration of CAR-T cells into the CNS and the release of proinflammatory cytokines, may contribute to direct neuronal damage and neuroinflammation, further exacerbating cognitive dysfunction. Diagnostic challenges in assessing neurocognitive changes in the context of CAR-T cell therapy include differentiating treatment-related toxicity from disease progression and other etiologies of cognitive impairment. Clinical evaluation, neuroimaging studies and biomarker assessments may aid in the diagnosis and monitoring of neurocognitive dysfunction, although standardized assessment tools and criteria for defining cognitive impairment are lacking [4].

***Address for Correspondence:** Clamp Tanakabatiya, Department of Neurology, Sapienza University of Rome, 00161 Rome, Italy, E-mail: clamptanakabatiya@hotmail.com*

Received: 01 April, 2024, Manuscript No. jcnn-24-134968; **Editor Assigned:** 03 April, 2024, PreQC No. P-134968; **Reviewed:** 15 April, 2024, QC No. Q-134968; **Revised:** 20 April 2024, Manuscript No. R-134968; **Published:** 27 April, 2024, DOI: 10.37421/2684-6012.2024.7.230

Discussion

The discussion of neurocognitive changes in patients undergoing CAR-T cell therapy encompasses several key points, including the mechanisms underlying cognitive dysfunction, the clinical manifestations and diagnostic challenges and strategies for management and supportive care. The multifactorial nature of neurocognitive changes in patients undergoing CAR-T cell therapy highlights the importance of a comprehensive approach to assessment and management. Strategies for mitigating cognitive sequelae include early recognition and prompt intervention, supportive care measures such as hydration, corticosteroids and cytokine-directed therapies for CRS and close monitoring of neurologic status and cognitive function. Furthermore, ongoing research efforts are needed to elucidate the pathophysiology of neurocognitive changes associated with CAR-T cell therapy, identify biomarkers predictive of cognitive impairment and develop targeted interventions to mitigate cognitive sequelae and improve patient outcomes. Longitudinal studies evaluating the long-term effects of CAR-T cell therapy on cognitive function and quality of life are essential for optimizing supportive care measures and informing clinical practice [5,6].

Conclusion

In conclusion, neurocognitive changes represent a significant clinical concern in patients undergoing CAR-T cell therapy for hematologic malignancies. The underlying mechanisms driving cognitive dysfunction are multifactorial and complex, involving CRS, immune-mediated neurotoxicity and CNS infiltration of CAR-T cells. Diagnostic challenges in assessing cognitive impairment underscore the need for standardized assessment tools and criteria for defining cognitive dysfunction. Despite these challenges, early recognition and prompt intervention are essential for mitigating cognitive sequelae and optimizing patient outcomes. Supportive care measures, including hydration, corticosteroids and cytokine-directed therapies, may help alleviate symptoms of neurotoxicity and improve cognitive function. Ongoing research efforts are needed to further elucidate the pathophysiology of neurocognitive changes associated with CAR-T cell therapy and develop targeted interventions to optimize supportive care and improve outcomes for patients undergoing this transformative treatment approach.

Acknowledgement

None.

Conflict of Interest

None.

References

1. De Marco, Rodrigo C., Hector J. Monzo and Päivi M. Ojala. "CAR T cell therapy: A versatile living drug." *Int J Mol Sci* 24 (2023): 6300.
2. Sievers, Savannah, Grace Watson, Swapna Johncy and Sherry Adkins. "Recognizing and grading CAR T-cell toxicities: An advanced practitioner perspective." *Front Oncol* 10 (2020): 885.
3. Lee, Daniel W., Bianca D. Santomasso, Frederick L. Locke and Armin Ghobadi, et al. "ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells." *Biol Blood Marrow Transplant* 25 (2019): 625-638.
4. Schmidts, Andrea, Marc Wehrli and Marcela V. Maus. "Toward better understanding and management of CAR-T cell–associated toxicity." *Annu Rev Med* 72 (2021): 365-382.
5. Tallantyre, Emma C., Nia A. Evans, Jack Parry-Jones and Matt PG Morgan, et al. "Neurological updates: Neurological complications of CAR-T therapy." *J Neurol* 268 (2021): 1544-1554.
6. Kazzi, Christina, Valeriya Kuznetsova, Pakeeran Siriratnam and Sarah Griffith, et al. "Cognition following chimeric antigen receptor T-cell therapy: A systematic review." *J Autoimmun* 140 (2023): 103126.

How to cite this article: Tanakabatiya, Clamp. "Navigating the Cognitive Terrain: Neurocognitive Changes in Patients Undergoing CAR-T Cell Therapy." *J Clin Neurol Neurosurg* 7 (2024): 230.